Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years

Learn more about:
Related Clinical Trial
DMCRN-02-001: Assessing Pediatric Endpoints in DM1 Myotonic Dystrophy Type 1 and Resistance Exercise Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AOC 1001 Administered Intravenously to Adult Myotonic Dystrophy Type 1 (DM1) Patients Biomarker Development for Muscular Dystrophies Extracellular RNA Biomarkers of Myotonic Dystrophy Symptoms and Outcome Measures for Upper- Limb Function in Myotonic Dystrophy Type 1 Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1 Poor Neck Proprioception May Cause Balance Deficits in Myotonic Dystrophy 1 Myotonic Dystrophy – Vascular and Cognition Effect of MYODM on Quality of Life, Fatigue and Hypersomnia in Patients With Myotonic Dystrophy Type 1 Open Label Study in Adolescents and Children With Myotonic Disorders European Home Mechanical Ventilation Registry Effects of SomatoKine (Iplex)Recombinant Human Insulin-like Growth Factor-1/Recombinant Human Insulin-like Growth Factor-binding Protein-3 (rhIGF-I/rhIGFBP-3) in Myotonic Dystrophy Type 1 (DM1) Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1 A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1 Sleep Breathing Disorders, a Main Trigger for Cardiac ARythmias in Type I Myotonic Dystrophy ? Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1 Effects of a 12-week Strength Training Program in Men With Myotonic Dystrophy Type 1 Efficacy and Safety of DHEA for Myotonic Dystrophy Study of Tideglusib in Adolescent and Adult Patients With Myotonic Dystrophy Effects of a Multiple Component Training Program on Muscles in Adults With Myotonic Dystrophy Type 1 Ventilatory Response After Non Invasive Ventilation in Type 1 Myotonic Dystrophy Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1 DM-IMT – Controlled, Randomized, Three-arm Intervention Study on the Safety and Efficacy of Regular Respiratory Muscle Training in Patients With Myotonic Dystrophy Type 1 Venous Thromboembolism in DM1 Postural Spirometry Changes in Ambulatory Myotonic Dystrophy Patients Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years PhenoDM1 (Myotonic Dystrophy Type 1 Natural History Study) Children’s Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) Observational Prolonged Trial in Myotonic Dystrophy Type 1 Venous Thromboembolism in Myotonic Dystrophy Type 1 Myotonic Dystrophy Type 1 Aerobic Exercise Study Multicenter Observational Study of Myotonic Dystrophy Type 1 DM1 Heart Registry – DM1 Respiratory Registry

Brief Title

Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years

Official Title

Factors Associated With Hypoventilation in the Myotonic Dystrophy, Progressive Profile Over 5 Years

Brief Summary

      The aim of this study is to determine the factors associated with alveolar hypoventilation in
      terms of cognitive impairment, daytime sleepiness, respiratory function, nocturnal
      respiratory events This evaluation will clarify the clinical phenotypes of respiratory
      disease in myotonic steinert dystrophy.
    



Study Type

Observational


Primary Outcome

Change of measurement of spirometry


Condition

Myotonic Dystrophy, Steinert


Study Arms / Comparison Groups

 PaCO2> 45 mmHg
Description:  Diurnal hypercapnia defined by PaCO2> 45 mmHg

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information



Estimated Enrollment

160

Start Date

June 30, 2010

Completion Date

September 2023

Primary Completion Date

September 2023

Eligibility Criteria

        Inclusion Criteria:

          -  Myotonic dystrophy of Steinert genetically confirmed (number of known CTG repeats), in
             its classical form of adult

        Exclusion Criteria:

          -  Inability to perform EFR assessment or polysomnography

          -  Moderate to severe asthma according to the GINA classification

          -  moderate to severe COPD (> stage 1 of the GOLD recommendations)

          -  Other significant respiratory pathology

          -  Patient already on NIV, CPAP or under oxygen therapy

          -  Impossibility of receiving enlightened information

          -  Inability to participate in the entire study
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Thierry Perez, MD, , [email protected]

Location Countries

France

Location Countries

France

Administrative Informations


NCT ID

NCT03764150

Organization ID

2009_04/0923

Secondary IDs

2009-A00588-49

Responsible Party

Sponsor

Study Sponsor

University Hospital, Lille


Study Sponsor

Thierry Perez, MD, Principal Investigator, University Hospital, Lille


Verification Date

January 2021